PsychoGenics Appoints John McCall, Ph.D. as Newest Member to its Scientific Advisory Board (SAB)

TARRYTOWN, N.Y., August 25, 2008 - PsychoGenics Inc., announces the appointment of John McCall, Ph.D., as a member of its Scientific Advisory Board, reflecting the company's growth in the areas of Drug Discovery and Development. Read More.

PsychoGenics Announces Positive Phase-IIa for its First-in-Class Partial 5-HT1A – 5-HT1B Receptor Agonist in ADHD

Tarrytown, N.Y., June 02, 2008 - PsychoGenics Inc. today announced positive data from its randomized, placebo controlled, multicenter, Phase IIa trial of eltoprazine, the company’s lead partial 5-HT1A – 5-HT1B receptor agonist, in adult patients with Attention Deficit/ Hyperactivity Disorder (ADHD). The primary objective of the exploratory study was to compare the effects of two doses of eltoprazine with placebo in a cross-over design on the symptoms of ADHD in adults using the total scores from the ADHD Rating Scale-Version IV.Read More.

PsychoGenics Appoints Bavani Shankar, as Vice President, Corporate Development

TARRYTOWN, N.Y., May 28, 2008 – PsychoGenics Inc., announced the appointment of Bavani Shankar, as Vice President of Corporate Development. This appointment reflects the company’s growth and expansion into new areas of CNS drug discovery and development.Read More.

PsychoGenics and Roche Enter Agreement to Identify New Treatments for Neuropsychiatric Disorders

Tarrytown, N.Y., May 27, 2008 - PsychoGenics Inc., and Roche, Basel, Switzerland, have entered into a drug discovery and development agreement in which they combine their complementary strengths and expertise to identify a new generation of treatments for neuropsychiatric disorders.Read More.

PsychoGenics and Dainippon Sumitomo Pharma Sign Drug Discovery Agreement

Tarrytown, NY, Mar 4, 2008 - PsychoGenics Inc. and Dainippon Sumitomo Pharma, Co., Ltd., Japan, have entered into a drug discovery agreement to screen selected Dainippon Sumitomo Pharma compounds in PsychoGenics’ proprietary Drug Discovery Systems, with the aim of identifying new therapies for CNS disorders. Read More.

PsychoGenics Expands Drug Discovery Relationship With Eli Lilly and Company

Tarrytown, NY, Jan 31, 2008 - PsychoGenics Inc. today announced that it has entered into an additional drug discovery agreement with Eli Lilly and Company (NYSE:LLY). Per the agreement, Lilly will supply pre-candidate compounds that PsychoGenics will evaluate using its proprietary drug discovery technologies, for the treatment of neuropsychiatric disorders.Read More.